Likely, we suspected that the mutated KIT and/or mutated WT1 could play a crucial role in the progression of low M-RiskScore AML patients, while mutations of NPM1 and/or RUNX1 endows worse progression in high M-RiskScore patients. The gene discussed is RUNX1; the disease is acute myeloid leukemia.